KN 387271

Drug Profile

KN 387271

Alternative Names: BAY 7271; BAY-387271; KN 38-7271

Latest Information Update: 20 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Developer KeyNeurotek Pharmaceuticals AG
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Craniocerebral trauma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain injuries; Stroke

Most Recent Events

  • 25 May 2011 Phase I development is ongoing in Germany
  • 25 May 2011 Phase II development is ongoing in Europe
  • 16 Dec 2009 Efficacy data from a phase II trial in traumatic brain injury released by KeyNeurotek
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top